Zacks: Brokerages Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Announce -$0.14 Earnings Per Share

Share on StockTwits

Brokerages predict that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will announce earnings per share (EPS) of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.13). Achillion Pharmaceuticals also posted earnings of ($0.14) per share in the same quarter last year. The business is scheduled to report its next earnings report on Wednesday, November 7th.

On average, analysts expect that Achillion Pharmaceuticals will report full-year earnings of ($0.52) per share for the current financial year, with EPS estimates ranging from ($0.55) to ($0.50). For the next year, analysts expect that the firm will report earnings of ($0.61) per share, with EPS estimates ranging from ($0.62) to ($0.60). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Achillion Pharmaceuticals.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01.

A number of analysts have issued reports on the stock. BidaskClub cut shares of Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. Finally, ValuEngine upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. Achillion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.38.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP lifted its stake in Achillion Pharmaceuticals by 0.3% in the second quarter. RTW Investments LP now owns 13,541,997 shares of the biopharmaceutical company’s stock valued at $38,324,000 after acquiring an additional 45,095 shares during the last quarter. BlackRock Inc. lifted its stake in Achillion Pharmaceuticals by 1.4% in the second quarter. BlackRock Inc. now owns 11,863,676 shares of the biopharmaceutical company’s stock valued at $33,575,000 after acquiring an additional 159,694 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Achillion Pharmaceuticals by 14.1% in the second quarter. Dimensional Fund Advisors LP now owns 6,892,184 shares of the biopharmaceutical company’s stock valued at $19,505,000 after acquiring an additional 849,721 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Achillion Pharmaceuticals by 1.9% in the second quarter. Northern Trust Corp now owns 1,604,822 shares of the biopharmaceutical company’s stock worth $4,541,000 after buying an additional 30,669 shares during the last quarter. Finally, Opaleye Management Inc. lifted its stake in shares of Achillion Pharmaceuticals by 148.9% in the first quarter. Opaleye Management Inc. now owns 1,095,100 shares of the biopharmaceutical company’s stock worth $4,063,000 after buying an additional 655,100 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

NASDAQ ACHN opened at $3.54 on Friday. The company has a market capitalization of $451.79 million, a price-to-earnings ratio of -5.71 and a beta of 1.03. Achillion Pharmaceuticals has a 12-month low of $2.33 and a 12-month high of $4.82.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply